Heron Therapeutics
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Heron Therapeutics sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).
Heron Therapeutics: 23 sponsored US clinical trials, none currently recruiting.
Heron Therapeutics sponsors 23 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 22 completed. 10 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Postoperative Pain, with 3 trials.
Top-decile sponsor footprint
Heron Therapeutics ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
22 of 23 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
23 total, page 1 of 1
HTX-011 in Spinal Surgery
NCT04911062
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.
NCT06109415
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE
NCT06109428
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
NCT04470622
Dose-Escalation Study of HTX-034 Following Bunionectomy
NCT04398329
HTX-011 Administration Study in Planned Caesarean Section Procedure
NCT03955211
Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen
NCT03974932
Study of Post-Herniorrhaphy Non-opioid MMA Regimens
NCT03907176
Phase 2 Bunionectomy HTX-011 Administration Study
NCT03718039
Phase 2 Herniorrhaphy Study for Opioid Elimination
NCT03695367
Bupivacaine HCl PK and Safety in Augmentation Mammoplasty
NCT03705065
Extended Delivery of Bupivacaine Study in Herniorrhaphy
NCT04102267
Bunionectomy Study for Postoperative Analgesia (EPOCH 1)
NCT03295721
Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)
NCT03237481
Phase 2B Upper Extremity Nerve Block Study
NCT03011333
Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia
NCT03015532
Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy
NCT02762929
Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery
NCT02689258
Pilot Herniorrhaphy Study for Postoperative Analgesia
NCT02504580
A Phase 2, Two-Part Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy
NCT02471898
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
NCT02106494
A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin
NCT01416259
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
NCT00343460
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 11 |
| Phase 3 | 6 |
| Phase 4 | 4 |
Therapeutic Areas
How the Heron Therapeutics archive is shaped
23 indexed studies, none listed as recruiting (0% open); 22 completed (96%).
Phase mix: 10 late (III/IV) vs 12 early (I/II) (balanced across stages).
Top condition: Postoperative Pain (3 trials), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Heron Therapeutics: archived-pipeline peers nationwide
Peers matched on 23 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Heron Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 23 archived trials
- AMAG Pharmaceuticals · 23 trials · 9% recruiting
- AtriCure · 23 trials · 22% recruiting
- Cara Therapeutics · 23 trials · 0% recruiting
- Craig L Slingluff, Jr · 23 trials · 4% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Heron Therapeutics page
23 registered trials is a research-attention snapshot, not an endorsement of Heron Therapeutics or any single study.
- None of Heron Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Postoperative Pain is the condition Heron Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Postoperative Pain trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Heron Therapeutics pipeline card: 23 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.